Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.

To identify better regimens in currently available chemotherapy would be beneficial to KRAS mutant metastatic colorectal cancer (mCRC) patients because they have fewer treatment options than KRAS wild-type mCRC patients. Clinicopathologic features and overall survival (OS) of KRAS mutant and wild-ty...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Yu-Lin Lin, Yi-Hsin Liang, Jia-Huei Tsai, Jau-Yu Liau, Jin-Tung Liang, Been-Ren Lin, Ji-Shiang Hung, Liang-In Lin, Li-Hui Tseng, Yih-Leong Chang, Kun-Huei Yeh, Ann-Lii Cheng
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Public Library of Science (PLoS) 2014-01-01
Seri Bilgileri:	PLoS ONE
Online Erişim:	http://europepmc.org/articles/PMC3913571?pdf=render
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.

Benzer Materyaller